3 Reasons Why Growth Investors Shouldn't Overlook Catalyst (CPRX)Zacks Investment Research • 03/16/23
Catalyst Pharmaceutical (CPRX) Q4 Earnings and Revenues Surpass EstimatesZacks Investment Research • 03/15/23
Catalyst Pharma The No. 1 Biotech, Just Crushed 2023 Guidance EstimatesInvestors Business Daily • 03/15/23
Catalyst Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 03/15/23
Catalyst Pharmaceuticals, Inc. (CPRX) is Attracting Investor Attention: Here is What You Should KnowZacks Investment Research • 03/10/23
Catalyst Pharmaceuticals Announces a Recent Third-Party Publication in Peer-Reviewed Journal Epilepsia Showing Perampanel (FYCOMPA®) Demonstrated High Efficacy in Patients with Rare Genetic EpilepsiesGlobeNewsWire • 03/08/23
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2022 Financial Results on March 15, 2023GlobeNewsWire • 03/01/23
Will Catalyst (CPRX) Beat Estimates Again in Its Next Earnings Report?Zacks Investment Research • 02/27/23
Catalyst Pharmaceuticals, Inc. (CPRX) Is a Trending Stock: Facts to Know Before Betting on ItZacks Investment Research • 02/27/23
Is Catalyst (CPRX) a Solid Growth Stock? 3 Reasons to Think "Yes"Zacks Investment Research • 02/24/23
Catalyst Pharmaceuticals to Ring the Nasdaq Closing Bell in Honor of International Rare Disease DayGlobeNewsWire • 02/22/23
Investors Heavily Search Catalyst Pharmaceuticals, Inc. (CPRX): Here is What You Need to KnowZacks Investment Research • 02/15/23
Is Catalyst (CPRX) a Buy as Wall Street Analysts Look Optimistic?Zacks Investment Research • 02/15/23
Catalyst Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2022 Total Revenues and Provides Full Year 2023 Revenue GuidanceGlobeNewsWire • 02/07/23
Catalyst Pharmaceuticals: Stable Upside Potential Amid Patent Infringement ConcernsSeeking Alpha • 02/01/23